Citations

Clear

4847 citation(s) found for "Yu, Eric".

Competency‐Based Assessment Tool for Pediatric Tracheotomy: International Modified Delphi Consensus
Propst, Evan J. , Wolter, Nikolaus E. , Ishman, Stacey L. , Balakrishnan, Karthik , Deonarain, Ashley R. , Mehta, Deepak, Zalzal, George H., Pransky, Seth M. , Roy, Soham , Myer, Charles M. , Torre, Michele , Johnson, Romaine F. , Lüdemann, Jeffrey P. , Derkay, Craig S. , Hong, Paul , Molter, David, Prager, Jeremy D. , Nguyen, Lily H. P. , Rutter, Michael J. , Zur, Karen B. , Sidell, Douglas R. , Johnson, Liane B. , Cotton, Robin T., Willging, J. Paul, Zdanski, Carlton J. , Manoukian, John J. , Lam, Derek J. , Gantwerker, Eric A. , Husein, Murad , Inglis, Andrew F., Green, Glenn E. , Javia, Luv, Schraff, Scott A. , Soma, Marlene , Deutsch, Ellen S. , Sobol, Steven E., Ida, Jonathan B., Choi, Sukgi S. , Uwiera, Trina C., Shah, Udayan K. , White, David R. , Wootten, Christopher T. , El‐Hakim, Hamdy , Bromwich, Matthew, Richter, Gresham T. , Vijayasekaran, Shyan , Smith, Marshall E. , Vaccani, Jean‐Philippe , Hartnick, Christopher J. , Faucett, Erynne A. , Sidell, Douglas R. , Hong, Paul , Prager, Jeremy D , Nguyen, Lily H P , Zur, Karen , Sidell, Douglas R , Hart, Catherine K , Gantwerker, Eric A , Husein, Murad , Choi, Sukgi , Hartnick, Christopher J , Faucett, Erynne A , Johnson, Romaine F , Sidell, Douglas R , Ishman, Stacey L , Lam, Derek J , Balakrishnan, Karthik , Chun, Robert H. , Hart, Catherine K. , Bauman, Nancy M.

Mayo Clinic

The Laryngoscope | December 10, 2019 | Volume: 130 | Issue: 11 | Pages: 2700-2707

10.1002/lary.28461 | PMID 31821571 Get It

Objectives/HypothesisCreate a competency‐based assessment tool for pediatric tracheotomy.Study DesignBlinded, modified, Delphi consensus process.MethodsUsing the REDCap database, a list of 31 potential items was circulated to 65 expert surgeons who perform pediatric tracheotomy. In the first round, items were rated as “keep” or “remove,” and comments were incorporated. In the second round, experts were asked to rate the importance of each item on a seven‐point Likert scale. Consensus criteria were determined a priori with a goal of 7 to 25 final items.ResultsThe first round achieved a response rate of 39/65 (60.0%), and returned questionnaires were 99.5% complete. All items were rated as “keep,” and 137 comments were incorporated. In the second round, 30 task‐specific and seven previously validated global rating items were distributed, and the response rate was 44/65 (67.7%), with returned questionnaires being 99.3% complete. Of the Task‐Specific Items, 13 reached consensus, 10 were near consensus, and 7 did not achieve consensus. For the 7 previously validated global rating items, 5 reached consensus and two were near consensus.ConclusionsIt is feasible to reach consensus on the important steps involved in pediatric tracheotomy using a modified Delphi consensus process. These items can now be considered to create a competency‐based assessment tool for pediatric tracheotomy. Such a tool will hopefully allow trainees to focus on the important aspects of this procedure and help teaching programs standardize how they evaluate trainees during this procedure.Level of Evidence5 Laryngoscope, 130:2700–2707, 2020
Brain imaging measurements of fibrillar amyloid‐β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele
Ghisays, Valentina , Goradia, Dhruman D., Protas, Hillary , Bauer, Robert, Devadas, Vivek, Tariot, Pierre N. , Lowe, Val J. , Petersen, Ronald C. , Caselli, Richard J. , Reiman, Eric M. , Knopman, David S. , Jack, Clifford R. , Su, Yi , Chen, Kewei

Mayo Clinic

Alzheimer's & Dementia | December 9, 2019 | Volume: 16 | Issue: 4 | Pages: 598-609

10.1016/j.jalz.2019.08.195 | PMID 31831374 Get It

AbstractIntroductionWe previously characterized associations between brain imaging measurements of amyloid‐β (Aβ) plaque burden and apolipoprotein E (APOE) ε4 gene dose in a small number of cognitively unimpaired late‐middle‐aged APOE ε4 homozygotes (HMs), heterozygotes (HTs), and noncarriers (NCs). We now characterize cross‐sectional Aβ plaque, tau tangle, and cortical atrophy (neurodegeneration) measurements, classifications, and associations with age in a larger number of unimpaired HMs, HTs, and NCs over a wider age range.MethodsWe analyzed 11C Pittsburgh compound B (Aβ) positron emission tomography (PET), flortaucipir (tau) PET, and volumetric magnetic resonance imaging data from 164 study participants of age 47–86 years, including 26 APOE ε4 HMs, 48 HTs, and 90 NCs matched for age and sex.ResultsAβ PET measurements rose, plateaued at the respective ages of 68 and 76, and then declined with age in unimpaired HM and HT groups. Compared with NCs, these two groups began to have significantly higher Aβ PET measurements at ages 62 and 70, respectively, and no longer had significantly higher measurements by ages 71 and 78, respectively. They began to have significantly higher entorhinal cortex tau PET measurements at ages 66 and 70, respectively, and no longer had significantly higher measurements by ages 74 and 78, respectively. Brain atrophy measurements tended to decline slowly with age in all three genetic groups. Their elevated tau PET measurements were attributable to those with positive Aβ PET scans. 41.0%, 18.0%, and 5.0% of the 47‐ to 70‐year‐old HMs, HTs, and NCs and 25.0%, 79.0%, and 38.0% of the 71‐ to 86‐year‐old HMs, HTs, and NCs had positive Aβ PET scans, and the long‐term recall memory scores are significantly higher in the older HMs than in HT and NC groups, suggesting resistance to Aβ deposition in those HMs who remained unimpaired at older ages.ConclusionsThis study provides information about Aβ plaque burden, tau tangle burden, and neurodegeneration in cognitively unimpaired persons at three levels of genetic risk for AD. Unimpaired APOE ε4 HMs can be studied before their 70s to evaluate the understanding of factors, processes, and interventions involved in the predisposition to and prevention of AD, and after their 70s, to discover factors, processes, and interventions involved in the resilience or resistance to and prevention of AD.
Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia
Zanwar, Saurabh , Abeykoon, Jithma P. , Durot, Éric , King, Rebecca L. , Burbano, Gabriela E. Perez, Kumar, Shaji , Gertz, Morie A. , Quinquenel, Anne , Gonsalves, Wilson I. , Cornillet‐Lefèbvre, Pascale , He, Rong , Warsame, Rahma , Novak, Anne J. , Greipp, Patricia T. , Inwards, David J. , Micallef, Ivana N. , Muchtar, Eli , Kourelis, Taxiarchis , Lacy, Martha Q. , Dingli, David , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Johnston, Patrick B. , Thanarajasingam, Gita , Lin, Yi , Kyle, Robert A. , Ansell, Stephen M. , Kapoor, Prashant , Perez Burbano, Gabriela E, Gonsalves, Wilson , Warsame, Rahma , Inwards, David, Micallef, Ivana, Kourelis, Taxiarchis , Dispenzieri, Angela , Witzig, T.E. , Villasboas, Jose, Leung, Nelson , Rajkumar, S Vincent , Ansell, Stephen M , Kapoor, Prashant , Gertz, Morie A , Muchtar, E , Dingli, David , Greipp, Patricia T , Lin, Yi , Quinquenel, Anne , Burbano, Gabriela Perez , Delmer, Alain , Buadi, Francis K. , Habermann, Thomas M. , Go, Ronald S. , Dispenzieri, Angela , Bennani, N. Nora , Witzig, Thomas E. , Villasboas, José C. , Leung, Nelson , Rajkumar, S. Vincent , Le‐Rademacher, Jennifer

Mayo Clinic

American Journal of Hematology | December 9, 2019 | Volume: 95 | Issue: 3 | Pages: 274-281

10.1002/ajh.25697 | PMID 31814157 Get It

AbstractHistological transformation in Waldenström macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88 L265P mutation on transformation. We examined risk factors and outcomes associated with transformation in WM, highlighting the role of MYD88 L265P mutation. Patients with WM seen at Mayo Clinic, Rochester, USA and University Hospital of Reims, France, between 01/01/1996 and December 31, 2017 were included; 50 (4.3%) of 1147 patients transformed to a high‐grade lymphoma, with median time‐to‐transformation of 4.5 (range 0‐21) years in the transformed cohort. The MYD88 L265P mutation status was known in 435/1147 (38%) patients (406 with non‐transformed WM and 29 patients in transformed cohort). On multivariate analysis, MYD88 WT status alone was an independent predictor of transformation (odds ratio, 7[95%CI: 2.1‐23]; P = .003). Additionally, the MYD88 WT status was independently associated with shorter time‐to‐transformation (HR 7.9 [95%CI: 2.3‐27; P = .001]), with a 5‐year transformation rate of 16% for MYD88 WT vs 2.8% with MYD88 L265P mutated patients. Patients with transformation demonstrated a significant increase in risk of death compared to patients who did not transform (HR 5.075; 95%CI: 3.8‐6.8; P < .001). In conclusion, the MYD88 WT status is an independent predictor of transformation and associated with a shorter time‐to‐transformation. Additionally, transformation conferred an inferior overall survival in patients with WM.
Predictors of nonroutine discharge among patients undergoing surgery for grade I spondylolisthesis: insights from the Quality Outcomes Database
Mummaneni, Praveen V. , Bydon, Mohamad , Knightly, John J. , Alvi, Mohammed Ali , Chan, Andrew K. , Biase, Michael, Strauss, Andrea, Glassman, Steven D. , Foley, Kevin T. , Slotkin, Jonathan R., Potts, Eric A. , Shaffrey, Mark E., Shaffrey, Christopher I. , Haid, Regis W., Fu, Kai-Ming, Wang, Michael Y. , Park, Paul , Asher, Anthony L. , Bisson, Erica F. , Alvi, Mohammed Ali , Goyal, Anshit , Guan, Jian , Strauss, Andrea

Mayo Clinic

Journal of Neurosurgery: Spine | December 6, 2019 | Volume: 32 | Issue: 4 | Pages: 523-532

10.3171/2019.9.spine19644 | PMID 31812142 Get It

OBJECTIVEDischarge to an inpatient rehabilitation facility or another acute-care facility not only constitutes a postoperative challenge for patients and their care team but also contributes significantly to healthcare costs. In this era of changing dynamics of healthcare payment models in which cost overruns are being increasingly shifted to surgeons and hospitals, it is important to better understand outcomes such as discharge disposition. In the current article, the authors sought to develop a predictive model for factors associated with nonroutine discharge after surgery for grade I spondylolisthesis.METHODSThe authors queried the Quality Outcomes Database for patients with grade I lumbar degenerative spondylolisthesis who underwent a surgical intervention between July 2014 and June 2016. Only those patients enrolled in a multisite study investigating the impact of fusion on clinical and patient-reported outcomes among patients with grade I spondylolisthesis were evaluated. Nonroutine discharge was defined as those who were discharged to a postacute or nonacute-care setting in the same hospital or transferred to another acute-care facility.RESULTSOf the 608 patients eligible for inclusion, 9.4% (n = 57) had a nonroutine discharge (8.7%, n = 53 discharged to inpatient postacute or nonacute care in the same hospital and 0.7%, n = 4 transferred to another acute-care facility). Compared to patients who were discharged to home, patients who had a nonroutine discharge were more likely to have diabetes (26.3%, n = 15 vs 15.7%, n = 86, p = 0.039); impaired ambulation (26.3%, n = 15 vs 10.2%, n = 56, p < 0.001); higher Oswestry Disability Index at baseline (51 [IQR 42–62.12] vs 46 [IQR 34.4–58], p = 0.014); lower EuroQol-5D scores (0.437 [IQR 0.308–0.708] vs 0.597 [IQR 0.358–0.708], p = 0.010); higher American Society of Anesthesiologists score (3 or 4: 63.2%, n = 36 vs 36.7%, n = 201, p = 0.002); and longer length of stay (4 days [IQR 3–5] vs 2 days [IQR 1–3], p < 0.001); and were more likely to suffer a complication (14%, n = 8 vs 5.6%, n = 31, p = 0.014). On multivariable logistic regression, factors found to be independently associated with higher odds of nonroutine discharge included older age (interquartile OR 9.14, 95% CI 3.79–22.1, p < 0.001), higher body mass index (interquartile OR 2.04, 95% CI 1.31–3.25, p < 0.001), presence of depression (OR 4.28, 95% CI 1.96–9.35, p < 0.001), fusion surgery compared with decompression alone (OR 1.3, 95% CI 1.1–1.6, p < 0.001), and any complication (OR 3.9, 95% CI 1.4–10.9, p < 0.001).CONCLUSIONSIn this multisite study of a defined cohort of patients undergoing surgery for grade I spondylolisthesis, factors associated with higher odds of nonroutine discharge included older age, higher body mass index, presence of depression, and occurrence of any complication.
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
Poorvu, Philip D. , Gelber, Shari , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Collins, Laura C. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Russell, Christy , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Jakubowski, Debbie , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | December 6, 2019 | Volume: 38 | Issue: 7 | Pages: 725-733

10.1200/jco.19.01959 | PMID 31809240 Get It

PURPOSE The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor–positive (ER+) and human epidermal growth factor receptor 2–negative (HER2−) breast cancer and is used to inform recommendations for chemotherapy. Women ≤ 40 years of age represent a minority of patients studied using gene expression profiles. METHODS The Young Women's Breast Cancer Study is a prospective cohort of women diagnosed with breast cancer at age ≤ 40 years and enrolled patients between 2006 and 2016 (N = 1,302). We identified patients with stage I-III ER+/HER2− breast cancer. The RS assay was performed on banked specimens for patients who had not been tested clinically. Distant recurrence-free survival (DRFS) was assessed by TAILORx and traditional RS risk groups among patients with axillary node–negative (N0) and limited node–positive (N1) breast cancer. RESULTS Among eligible women (N = 577), 189 (33%) had undergone RS testing, and 320 (56%) had banked specimens sufficient for testing. Median follow-up was 6.0 years. Median age at diagnosis was 37.2 years; 300 of 509 patients (59%) had N0 breast cancer, of whom 195 (65%) had an RS of 11-25 and fewer than half (86 of 195; 44%) received chemotherapy. Six-year DRFS rates were 94.4% and 92.3% (RS < 11), 96.9% and 85.2% (RS 11-25), and 85.1% and 71.3% (RS ≥ 26) among women with N0 and N1 disease, respectively. CONCLUSION The RS assay is prognostic among young women with node-negative and limited node-positive breast cancer, representing a valuable tool for risk stratification. Disease outcomes with a median follow-up of 6 years among young women with N0 disease and an RS of 0-25, a minority of whom received chemotherapy, and node-positive disease with an RS < 11 were very good, whereas those with N0 disease and an RS ≥ 26 or N1 disease with an RS ≥ 11 experienced substantial risk of early distant recurrence.
Individualized medicine: Sex, hormones, genetics, and adverse drug reactions
Moyer, Ann M. , Matey, Eric T. , Miller, Virginia M.

Mayo Clinic

Pharmacology Research & Perspectives | December 6, 2019 | Volume: 7 | Issue: 6 | Pages: No page available

10.1002/prp2.541 | PMID 31844524 Get It

AbstractClinically relevant adverse drug reactions differ between men and women. The underlying physiological and pharmacological processes contributing to these differences are infrequently studied or reported. As gene expression, cellular regulatory pathways, and integrated physiological functions differ between females and males, aggregating data from combined groups of men and women obscures the ability to detect these differences. This paper summarizes how genetic sex, that is, the presence of sex chromosomes XY for male or XX for female, and the influence of sex hormones affect transporters, receptors, and enzymes involved in drug metabolism. Changing levels of sex steroids throughout life, including increases at puberty, changes with pregnancy, and decreases with age, may directly and indirectly affect drug absorption, distribution, metabolism, and elimination. The direct and indirect effects of sex steroids in the form of exogenous hormones such as those used in hormonal contraceptives, menopausal hormone treatments, transgender therapy, and over‐the‐counter performance enhancing drugs may interfere with metabolism of other pharmaceuticals, and these interactions may vary by dose, formulation, and mode of delivery (oral, injection, or transdermal) of the steroid hormones. Few drugs have sex‐specific labeling or dosing recommendations. Furthermore, there is limited literature evaluating how the circulating levels of sex steroids impact drug efficacy or adverse reactions. Such research is needed in order to improve the understanding of the impact of sex hormones on pharmacological therapies, particularly as medicine moves toward individualizing treatments.
Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/RAB4 expression and mTOR activation
Godavarthy, Aparna, Jimah, John R. , Beckford, Miguel, Caza, Tiffany , Fernández, David , Huang, Nick , Duarte, Manuel, Fadel, Hind J., Poeschla, Eric M. , Bánki, Katalin, Perl, András , Kelly, Ryan, Fernández, David , Lewis, Joshua Richard

Mayo Clinic

JCI Insight | December 5, 2019 | Volume: 5 | Issue: 1 | Pages: No page available

10.1172/jci.insight.134010 | PMID 31805010 Get It

Overexpression and long terminal repeat (LTR) polymorphism of the HRES‑1/Rab4 human endogenous retrovirus locus have been associated with T cell activation and disease manifestations in systemic lupus erythematosus (SLE). Although genomic DNA methylation is diminished overall in SLE, its role in HRES-1/Rab4 expression is unknown. Therefore, we determined how lupus-associated polymorphic rs451401 alleles of the LTR regulate transcription from the HRES-1/Rab4 promoter and thus affect T cell activation. The results showed that cytosine –119 is hypermethylated while cytosine –51 of the promoter and the LTR enhancer are hypomethylated in SLE. Pharmacologic or genetic inactivation of DNA methyltransferase 1 augmented the expression of HRES-1/Rab4. The minimal promoter was selectively recognized by metabolic stress sensor NRF1 when cytosine –119 but not cytosine –51 was methylated, and NRF1 stimulated HRES-1/Rab4 expression in human T cells. In turn, IRF2 and PSIP1 bound to the LTR enhancer and exerted control over HRES-1/Rab4 expression in rs451401 genotype– and methylation-dependent manners. The LTR enhancer conferred markedly greater expression of HRES-1/Rab4 in subjects with rs451401CC over rs451401GG alleles that in turn promoted mechanistic target of rapamycin (mTOR) activation upon T cell receptor stimulation. HRES-1/Rab4 alone robustly activated mTOR in human T cells. These findings identify HRES-1/Rab4 as a methylation- and rs451401 allele–dependent transducer of environmental stress and controller of T cell activation.
Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
Mehrotra, Shailly , Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford A. , Lyss, Alan P., Toppmeyer, Deborah , Moreno‐Aspitia, Alvaro , Lad, Thomas E. , Velasco, Mario R. , Overmoyer, Beth , Ratain, Mark J. , Sharma, Manish R. , Gray, Elizabeth, Winer, Eric P. , Rugo, Hope S. , Gobburu, Jogarao , Sharma, Manish R.

Mayo Clinic

The Journal of Clinical Pharmacology | December 5, 2019 | Volume: 60 | Issue: 4 | Pages: 444-452

10.1002/jcph.1559 | PMID 31802506 Get It

AbstractChemotherapy‐induced peripheral neuropathy (henceforth, neuropathy) is often dose limiting and is generally managed by empirical dose modifications. We aimed to (1) identify an early time point that is predictive of future neuropathy using a patient‐reported outcome and (2) propose a dose‐adjustment algorithm based on simulated data to manage neuropathy. In previous work, a dose‐neuropathy model was developed using dosing and patient‐reported outcome data from Cancer and Leukemia Group B 40502 (Alliance), a randomized phase III trial of paclitaxel, nanoparticle albumin–bound paclitaxel or ixabepilone as first‐line chemotherapy for locally recurrent or metastatic breast cancer. In the current work, an early time point that is predictive of the future severity of neuropathy was identified based on predictive accuracy of the model. Using the early data and model parameters, simulations were conducted to propose a dose‐adjustment algorithm for the prospective management of neuropathy in individual patients. The end of the first 3 cycles (12 weeks) was identified as the early time point based on a predictive accuracy of 75% for the neuropathy score after 6 cycles. For paclitaxel, nanoparticle albumin–bound paclitaxel, and ixabepilone, simulations with the proposed dose‐adjustment algorithm resulted in 61%, 48%, and 35% fewer patients, respectively, with neuropathy score ≥8 after 6 cycles compared to no dose adjustment. We conclude that early patient‐reported outcome data on neuropathy can be used to guide dose adjustments in individual patients that reduce the severity of future neuropathy. Prospective validation of this approach should be undertaken in future studies.
Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care
Navari, Rudolph M. , Ruddy, Kathryn J. , LeBlanc, Thomas W. , Clark-Snow, Rebecca, Wickham, Rita , Binder, G. , Coberly, Tammy Bratton, Schmerold, Luke, Roeland, Eric , Leblanc, Thomas , Roeland, Eric J , Potluri, Ravi C.

Mayo Clinic

JCO Oncology Practice | December 4, 2019 | Volume: 16 | Issue: 2 | Pages: e132-e138

10.1200/jop.19.00457 | PMID 31800352 Get It

PURPOSE: After ASCO and National Comprehensive Cancer Network guideline recommendations for triple antiemetic prophylaxis for carboplatin area under the curve (AUC) ≥ 4, and the publication of studies documenting avoidable acute care after chemotherapy involving nausea and vomiting (NV) and other toxicities, we studied clinician adherence to the guideline change and assessed avoidable acute-care use. METHODS: Using a large electronic health record database, we evaluated antiemetic prophylaxis as recommended in the guidelines and post-chemotherapy avoidable acute-care use (defined as involving any of NV or 8 other toxicities) for patients initiating carboplatin or other chemotherapy from October 2012 to August 2018. RESULTS: We identified 11,554 carboplatin courses. After the guideline change adding neurokinin-1 receptor antagonists (RAs) for carboplatin AUC ≥ 4, its use rose to 20% of courses from the prior average of 16%; virtually all courses also included a 5-HT3 RA plus dexamethasone. We found avoidable acute care in 23% of courses; one quarter of these events were associated with NV. Acute care rates after carboplatin mirrored those after other highly emetogenic chemotherapy or oxaliplatin and exceeded those after other chemotherapy regimens. The > 80% shortfall in adherence may have been caused by low awareness or acceptance of the guideline change and/or by poor awareness of avoidable acute-care use after carboplatin. CONCLUSION: Neurokinin-1 RA prophylaxis for carboplatin AUC ≥ 4 remains low and largely unchanged despite National Comprehensive Cancer Network and ASCO 2017 recommendations for inclusion. NV and avoidable acute care involving NV seen after carboplatin were consistent with other highly emetogenic chemotherapy. Clinician action is required to remediate incomplete prophylaxis and to no longer place patient outcomes, resources for cancer treatment, and clinician reimbursement at risk.